Saurabh Saha Sells 2,592 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA) CEO Saurabh Saha sold 2,592 shares of the firm’s stock in a transaction dated Wednesday, October 23rd. The stock was sold at an average price of $15.32, for a total value of $39,709.44. Following the completion of the sale, the chief executive officer now directly owns 630,661 shares in the company, valued at $9,661,726.52. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Saurabh Saha also recently made the following trade(s):

• On Monday, October 21st, Saurabh Saha sold 22,205 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $15.80, for a total value of $350,839.00.
• On Friday, September 20th, Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $16.53, for a total value of $909,150.00.
• On Tuesday, September 10th, Saurabh Saha sold 175,000 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $16.52, for a total transaction of $2,891,000.00.
• On Thursday, August 22nd, Saurabh Saha sold 506 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $12.23, for a total transaction of $6,188.38.
• On Tuesday, August 20th, Saurabh Saha sold 4,169 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $12.32, for a total transaction of $51,362.08.

Centessa Pharmaceuticals Stock Performance

Shares of Centessa Pharmaceuticals stock opened at $15.50 on Friday. Centessa Pharmaceuticals plc has a 1 year low of $5.58 and a 1 year high of $17.59. The firm’s 50-day moving average is $14.93 and its 200 day moving average is $11.45. The stock has a market cap of $1.56 billion, a price-to-earnings ratio of -10.67 and a beta of 1.46. The company has a debt-to-equity ratio of 0.27, a current ratio of 13.29 and a quick ratio of 13.29.

Centessa Pharmaceuticals (NASDAQ:CNTA) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.02). Sell-side analysts anticipate that Centessa Pharmaceuticals plc will post -1.68 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have weighed in on CNTA. Oppenheimer reaffirmed an “outperform” rating and set a $14.00 price objective on shares of Centessa Pharmaceuticals in a research report on Wednesday, August 14th. BMO Capital Markets upped their price target on Centessa Pharmaceuticals from $20.00 to $35.00 and gave the stock an “outperform” rating in a research note on Monday, September 16th. Jefferies Financial Group raised their price objective on Centessa Pharmaceuticals from $13.00 to $19.00 and gave the company a “buy” rating in a research report on Wednesday, September 11th. Guggenheim upped their target price on shares of Centessa Pharmaceuticals from $20.00 to $24.00 and gave the stock a “buy” rating in a research report on Wednesday, September 11th. Finally, B. Riley started coverage on shares of Centessa Pharmaceuticals in a research report on Thursday, September 19th. They set a “buy” rating and a $33.00 price target for the company. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Centessa Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $25.17.

Institutional Investors Weigh In On Centessa Pharmaceuticals

Several institutional investors have recently modified their holdings of the business. Mirae Asset Global Investments Co. Ltd. lifted its stake in Centessa Pharmaceuticals by 47.7% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,556 shares of the company’s stock valued at $40,000 after acquiring an additional 826 shares during the period. GAMMA Investing LLC lifted its position in Centessa Pharmaceuticals by 103.1% during the third quarter. GAMMA Investing LLC now owns 2,972 shares of the company’s stock valued at $48,000 after purchasing an additional 1,509 shares during the period. Quarry LP lifted its position in Centessa Pharmaceuticals by 47.8% during the second quarter. Quarry LP now owns 9,608 shares of the company’s stock valued at $87,000 after purchasing an additional 3,108 shares during the period. EntryPoint Capital LLC purchased a new stake in Centessa Pharmaceuticals in the first quarter worth approximately $109,000. Finally, Sandia Investment Management LP bought a new stake in Centessa Pharmaceuticals in the 2nd quarter worth approximately $90,000. 82.01% of the stock is owned by hedge funds and other institutional investors.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.